Transgenomic Company Profile (NASDAQ:PRPO)

About Transgenomic (NASDAQ:PRPO)

Transgenomic logoPrecipio, Inc., formerly Transgenomic, Inc., is a biotechnology company. The Company is engaged in advancing personalized medicine for the detection and treatment of cancer, and inherited diseases through its molecular technologies and clinical and research services. The Company operates through its Laboratory Services segment. The Company is engaged in the provision of its Multiplexed ICE COLD-PCR (MX-ICP) product to the clinical market, enabling the use of blood and other bodily fluids for diagnosis, monitoring and treatment of cancer. MX-ICP amplifies the ability to detect genetic mutations by approximately 100 to 400 fold. MX-ICP is validated internally on sequencing platforms, including Sanger, Next Gen Sequencing and Digital polymerase chain reaction (PCR). Its laboratory in Omaha, Nebraska is focused on providing genetic analytical services related to oncology and pharmacogenomics research services supporting Phase II and Phase III clinical trials conducted.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: N/A
  • Symbol: NASDAQ:PRPO
  • CUSIP: N/A
  • Web:
  • Market Cap: $14.94 million
  • Outstanding Shares: 8,121,000
Average Prices:
  • 50 Day Moving Avg: $2.02
  • 200 Day Moving Avg: $4.84
  • 52 Week Range: $1.51 - $20.00
  • Trailing P/E Ratio: N/A
  • P/E Growth: 0.00
  • Net Margins: -536.28%
  • Return on Assets: -108.93%
  • Debt-to-Equity Ratio: 0.01%
  • Current Ratio: 0.11%
  • Quick Ratio: 0.10%
  • Average Volume: 69,106 shs.
  • Beta: 0.07

Frequently Asked Questions for Transgenomic (NASDAQ:PRPO)

What is Transgenomic's stock symbol?

Transgenomic trades on the NASDAQ under the ticker symbol "PRPO."

When did Transgenomic's stock split? How did Transgenomic's stock split work?

Transgenomic's stock reverse split before market open on Tuesday, June 6th 2017. The 1-30 reverse split was announced on Thursday, May 25th 2017. The number of shares owned by shareholders was adjusted after the market closes on Monday, June 5th 2017. An investor that had 100 shares of Transgenomic stock prior to the reverse split would have 3 shares after the split.

How were Transgenomic's earnings last quarter?

Transgenomic, Inc. (NASDAQ:PRPO) released its quarterly earnings data on Friday, August, 12th. The company reported ($3.00) earnings per share (EPS) for the quarter. The business earned $0.51 million during the quarter. View Transgenomic's Earnings History.

Who are some of Transgenomic's key competitors?

Who are Transgenomic's key executives?

Transgenomic's management team includes the folowing people:

  • Robert M. Patzig, Independent Chairman of the Board
  • Ilan Danieli, President, Chief Executive Officer, Director
  • Carl R Iberger, Chief Financial Officer
  • Mark Rimer, Director
  • Jeffrey Cossman, Independent Director
  • Douglas Fisher M.D., Independent Director
  • Michael A. Luther Ph.D., Independent Director
  • Samuel D. Riccitelli, Independent Director

Who owns Transgenomic stock?

Transgenomic's stock is owned by a number of of institutional and retail investors. Top institutional investors include RIMER MARK (20.00%) and RIMER MARK (14.30%). View Institutional Ownership Trends for Transgenomic.

How do I buy Transgenomic stock?

Shares of Transgenomic can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Transgenomic's stock price today?

One share of Transgenomic stock can currently be purchased for approximately $1.84.

MarketBeat Community Rating for Transgenomic (NASDAQ PRPO)
Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  41 (Vote Outperform)
Underperform Votes:  39 (Vote Underperform)
Total Votes:  80
MarketBeat's community ratings are surveys of what our community members think about Transgenomic and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Transgenomic (NASDAQ:PRPO) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A
Consensus Price Target History for Transgenomic (NASDAQ:PRPO)
Price Target History for Transgenomic (NASDAQ:PRPO)
Analysts' Ratings History for Transgenomic (NASDAQ:PRPO)
No equities research coverage for this company has been tracked by


Earnings History for Transgenomic (NASDAQ:PRPO)
Earnings by Quarter for Transgenomic (NASDAQ:PRPO)
Earnings History by Quarter for Transgenomic (NASDAQ PRPO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/12/2016Q216($3.00)$0.51 millionViewListenView Earnings Details
5/23/2016Q116($3.00)$0.24 millionViewListenView Earnings Details
11/12/2015Q315($8.10)($5.40)$6.65 million$4.00 millionViewListenView Earnings Details
8/13/2015Q215($12.30)($9.00)$7.10 million$7.00 millionViewListenView Earnings Details
5/14/2015Q115($15.60)($10.80)$6.80 million$6.51 millionViewListenView Earnings Details
4/15/2015Q414($16.80)($23.10)$6.20 million$7.70 millionViewN/AView Earnings Details
10/30/2014($17.40)($18.30)$6.80 million$6.37 millionViewN/AView Earnings Details
5/7/2014($14.10)($18.00)$6.73 million$6.25 millionViewN/AView Earnings Details
3/12/2014($10.80)($1.50)$6.71 million$6.22 millionViewN/AView Earnings Details
8/6/20132Q13($0.90)($0.90)ViewN/AView Earnings Details
5/8/20131Q13($0.90)($1.20)ViewN/AView Earnings Details
3/13/20134Q12($0.90)($0.90)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Transgenomic (NASDAQ:PRPO)

No earnings estimates for this company have been tracked by


Dividend History for Transgenomic (NASDAQ:PRPO)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Transgenomic (NASDAQ:PRPO)
Insider Ownership Percentage: 1.90%
Institutional Ownership Percentage: 6.72%
Insider Trades by Quarter for Transgenomic (NASDAQ:PRPO)
Insider Trades by Quarter for Transgenomic (NASDAQ:PRPO)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/22/2014Leroy C KoppMajor ShareholderSell413,050$3.70$1,528,285.00View SEC Filing  
10/2/2013Leroy C KoppMajor ShareholderBuy9,000$0.39$3,510.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Transgenomic (NASDAQ:PRPO)
Latest Headlines for Transgenomic (NASDAQ:PRPO)
Loading headlines, please wait.



Transgenomic (PRPO) Chart for Sunday, October, 22, 2017

This page was last updated on 10/22/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.